Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients
J Eur Acad Dermatol Venereol
.
2022 Oct;36(10):e838-e841.
doi: 10.1111/jdv.18314.
Epub 2022 Jun 22.
Authors
L Mastorino
1
,
F Castelli
2
,
E Stroppiana
1
,
A Verrone
1
,
M Ortoncelli
1
,
S Susca
1
,
S Boskovic
1
,
S G Passerini
1
,
N Macagno
1
,
C Cariti
1
,
M Licciardello
2
,
C Solaroli
2
,
G Pertusi
3
,
M G Aragone
4
,
G Baggini
4
,
C Addese
5
,
C Leporati
5
,
R Peila
5
,
M T Giura
6
,
G Rossotto
6
,
P Pella
7
,
L Mocci
8
,
G Merlo
8
,
R Tiberio
9
,
F Graziola
9
,
P Quaglino
1
,
P Dapavo
1
,
S Ribero
1
Affiliations
1
Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
2
Section of Dermatology, Koelliker Hospital, Turin, Italy.
3
Outpatient Clinic, Section of Dermatology, ASL VC, Vercelli, Italy.
4
Outpatient Clinic, Section of Dermatology, ASL AL, Alessandria, Italy.
5
Outpatient Clinic, Section of Dermatology, ASLTO4, Ivrea, Italy.
6
Surgery Department, Section of Dermatology, Cardinal Massaia Hospital, ASL AT, Asti, Italy.
7
Oncology Department, Section of Dermatology, Degli Infermi Hospital, ASL BI, Biella, Italy.
8
Section of Dermatology, AO AL Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
9
Dermatologic Clinic, AOU Maggiore della Carità Hospital, Novara, Italy.
PMID:
35686942
DOI:
10.1111/jdv.18314
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal*
Humans
Psoriasis* / drug therapy
Substances
Antibodies, Monoclonal
risankizumab